Ouhua Meike Secures RMB 100 Million Series B Funding Led by Cathay Capital to Accelerate Global Expansion

VCBeat has learned that,Following the Series A investment by Honghui Capital, Ouhua Meike recently securedCathay Capital’s Series B investment of approximately RMB 100 million in equivalent USD will continue to deepen its engagement in the medical aesthetics industry.Ouhua Meike is a leading Chinese manufacturer, seller, and service provider of medical technological equipment for dermatological aesthetics. This round of financing will primarily help Ouhua Meike continue to expand and refine its product portfolio, strengthen market development, and pursue investments in and acquisitions of high-quality overseas enterprises.

After years of market education and cultivation, the medical aesthetics industry has entered a phase of rapid growth. Demand for the procurement and upgrading of medical-grade equipment has surged among beauty salons, private hospitals, and other relevant medical institutions, while the trend toward home-use beauty devices continues to gain momentum. According to data from EIU and Kearney, the market size of China’s medical aesthetics device sector was RMB 11.3 billion in 2015 and is projected to reach RMB 24.2 billion by 2018. However, compared with countries such as the United States, Japan, South Korea, and Brazil, China’s market penetration rate remains low, indicating substantial growth potential for the overall market.

Ohua Medical (Group) was established in 2012,It is an international group enterprise specializing in dermatological medical technology and global research on the industrialization of aesthetics, with its headquarters in Beijing. Leveraging the support of three major medical investment groups—Beitou, Dongtou, and Nantou—it has a nationwide presence. The company currently employs over 1,500 people and generates an annual output value of nearly USD 200 million.

In terms of core products, Ouhua Meike boasts a rich portfolio of existing and pipeline products, covering devices, instruments, biological dermal fillers, and pharmaceuticals. Its offerings span three market tiers: medical-grade, aesthetic-grade, and home-use. The company provides comprehensive total solutions for medical aesthetic services, including market operation analysis, management, quality control, technical training, and maintenance, earning a strong reputation in the market.

Furthermore, leveraging capital investment as a strategic link, Ouhua Meike has secured upstream R&D and manufacturing capabilities for medical aesthetic devices through acquisitions and controlling stakes. The company has invested in multiple overseas technology-driven enterprises with proprietary intellectual property, including Endymed (an Israeli photoelectric aesthetic device manufacturer), Digital Makeup (a skin detection technology developer), and Bioxis (a French developer of next-generation dermal fillers). Through these investments, Ouhua Meike has obtained core technologies for various high-end devices and products worldwide, as well as long-term exclusive marketing rights in China. The company operates three R&D and manufacturing centers in Israel, China, and France.

Currently,Endymed’s Pro radiofrequency platform and the NEWA home-use beauty device, both under the Ouhua umbrella, have already been launched in the medical channel. Upcoming releases will include Endymed’s high-end triple-wavelength hair removal system, Bioxis’s hyaluronic acid-chitosan products from France, and French dermocosmetic lines.

In China, Ouhua Meike primarily invests in the research and development and sales of dermatological medical technology products and equipment (EndyMed, Formatk, Gemenshi), as well as in the investment and M&A of service terminals for medical aesthetic institutions (specialized hospitals) and non-medical aesthetic institutions (OUHUA JUVA chain of cosmetic dermatology clinics). The company possesses efficient industrial integration capabilities in investment, management, technological R&D, and education.

Clearly, Ouhua has established a strong competitive advantage in the upstream medical aesthetics device industry, driven by its global R&D capabilities, patented technology barriers, and a robust portfolio of advanced products. Following Cathay Capital’s investment, it will continue to support Ouhua Meike’s international team in introducing high-quality foreign products and exporting Chinese-made devices to multiple overseas countries and regions, thereby meeting the diverse needs of customers across different markets.

In the future, Ouhua Meike will continue to strengthen its efforts in independent intellectual property R&D, overseas mergers and acquisitions, and product introduction, focusing on the home consumer, medical aesthetics, and professional beauty markets to build an innovative multinational medical aesthetics platform.

Regarding this collaboration, Mr. Yuan Bing, Founder and General Manager of Ouhua Meike, stated that Cathay Capital possesses in-depth understanding and experience in the medical aesthetics sector. In particular, Cathay Capital’s local teams in Europe and the United States are well-versed in regional industry developments. He expressed confidence that this will play a unique role in facilitating future collaborations or investments between Ouhua Meike and high-quality overseas enterprises.

Mr. Yuan Bing possesses over 15 years of investment experience in the fields of medical aesthetics and lifestyle beauty. He has established more than 20 medical aesthetic clinics and 100 chain beauty institutions in China. Over the past decade, he successfully built professional markets in China for the Israeli medical laser companies Alma and Syneron. In July 2014, he successfully acquired the Israeli medical device company EndyMed, marking it as the first Chinese-controlled enterprise listed on the Israeli capital market.

Mr. Cai Mingpo, Founder and Chairman of Cathay Capital, stated that China’s medical aesthetics market is experiencing rapid growth. Ouhua Meike holds multiple technological patents, and its team comprises some of the earliest founders and management professionals in China’s medical aesthetics sector, boasting extensive industry experience and a long-term strategic vision. Following Cathay Capital’s investment in Ouhua Meike, it is believed that the company’s global supply chain integration and market expansion capabilities will be strengthened. Furthermore, Cathay Capital will assist Ouhua Meike in continuing cross-border mergers and acquisitions and identifying new product lines for medical aesthetic devices, thereby driving faster and more robust comprehensive internationalization.